The CEO's $250K open-market buy alongside a director's $120K buy on the same day is a strong cluster-buy signal. Monitor for upcoming catalysts such as earnings, pipeline updates, or partnership announcements that may have motivated the purchases. The absence of any insider sales in the window reinforces the bullish read.
Price Chart
Executive Summary
Two insiders at Retension Pharmaceuticals, including CEO Eric Keller and Director Franklin Berger, made open-market purchases totaling $370K at $12/share on October 13, 2026. The CEO's $250K buy and the director's $120K buy represent a strong bullish signal, as cluster buys by C-suite executives are among the most predictive insider signals per academic literature.
Key Financial Metrics
Key Facts
- CEO Eric Keller purchased 20,800 shares for $250K in an open-market transaction on October 13, 2026.
- Director Franklin Berger purchased 10,000 shares for $120K in an open-market transaction on October 13, 2026.
- Total open-market purchases by insiders: $370K.
- Multiple directors also converted derivatives and received grants (non-cash transactions) on the same date, indicating routine equity compensation vesting.
- No open-market sales were reported in the cluster window.
Financial Impact
Total insider open-market purchases of $370K represent approximately 0.11% of the company's $326M market cap (based on $12/share price and ~27.2M shares outstanding).
Risk Factors
- The purchases represent a small fraction of market cap (0.11%), limiting the signal's magnitude.
- Insider buys can be driven by factors other than fundamental outlook (e.g., option exercise timing, personal portfolio rebalancing).
- No other C-suite officers (e.g., COO) participated in open-market buys, reducing the cluster's breadth.
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RTSN-1791929582687 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $15.25 | awaiting T+5 | — | $13.52 (−11.34%) |
Oct 16, 2026 11d ago | SC 13G | $16.33 $14.65 | ▼ −10.29% | ▼ −10.14% | $13.52 (−17.21%) |
Oct 16, 2026 11d ago | SC 13G | $14.07 $15.25 | ▲ +8.39% | ▲ +8.82% | $13.52 (−3.91%) |
Oct 15, 2026 12d ago | SC 13G | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $13.52 (+10.73%) |
Oct 14, 2026 13d ago | SC 13D | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $13.52 (+10.73%) |
Oct 13, 2026 14d ago | Insider Cluster | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $13.52 (+16.15%) |
Oct 13, 2026 14d ago | 3 | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $13.52 (+16.15%) |
Oct 9, 2026 18d ago | 424B4 | $11.32 $16.33 | ▲ +44.26% | ▲ +45.75% | $13.52 (+19.43%) |
Oct 9, 2026 18d ago | EFFECT | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $13.52 (+28.40%) |
Oct 8, 2026 19d ago | 3 | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $13.52 (+28.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers